Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cilengitide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-20 of 20 for your search:
Start Over
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMD 121974-011, EORTC 26071-22072, 2007-004344-78, NCT00689221
Phase I/II Study of EMD 121974 in Patients With Progressive or Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-9911, JHOC-NABTT-9911, NCT00006093
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02932, NABTT 0306, CDR0000368451, U01CA062475, ABTC-0306, NCT00085254
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 200052-013, 2008-000615-15, NCT00705016
Phase II Randomized Study of Cilengitide in Patients With Recurrent or Progressive Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCLA-0408014-01, EMD-121974-009, MERCK-EMD-121974-009, NCT0093964
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02653, CDR0000428409, NABTC-03-02, U01CA062399, NCT00112866
Cilengitide in Treating Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03066, 2004-045, N01CM62206, CDR0000438708, CCUM-2004-045, 6735, NCI-6735, NCT00121238
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: H2007-0087, CO05601, NCT00590824
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2009-00339, COG-ACNS0621, CDR0000595623, ACNS0621, U10CA098543, NCT00679354
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMD 121974-012, NCT00813943
Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 200037-014, EudraCT Number: 2008-004148-35, NCT00842712
Cilengitide in Treating Patients With Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02904, UMCC 2004.030, N01CM62202, CCUM-2004-030, NCI-6372, 6372, UCSF-045512, UCSF-H45860-26715-01B, NCT00103337
EMD 121974 in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02392, 00-1096, U01CA099176, CDR0000068786, UCHSC-001096, NCI-3358, 3358, NCT00022113
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02569, UCCRC-12774A, CDR0000349535, NCI-6362, 6362, NCT00077155
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 9909-40; T99-0076, IUMC-9909-40, NCI-T99-0076, T99-0076, NCT00004258
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-03175, CDR653715, PBTC-012, U01CA081457, NCT00063973
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02919, CDR0000654715, 0903, ABTC-0903, U01CA137443, NCT00979862
Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 07 POUM 01, NCT01118676
Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CILENT-0902, NCT01165333
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00619, U01CA069912, MC0915, 8335, P30CA015083, MAYO-MC0915, NCT01276496
Start Over